ME01267B - 4-fenilaminokinazolin-6-ilamidi - Google Patents
4-fenilaminokinazolin-6-ilamidiInfo
- Publication number
- ME01267B ME01267B MEP-2012-2A MEP212A ME01267B ME 01267 B ME01267 B ME 01267B ME P212 A MEP212 A ME P212A ME 01267 B ME01267 B ME 01267B
- Authority
- ME
- Montenegro
- Prior art keywords
- fluorophenylamino
- chloro
- amide
- enoic acid
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 12
- 241000124008 Mammalia Species 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 230000002159 abnormal effect Effects 0.000 claims 3
- 230000010261 cell growth Effects 0.000 claims 3
- LVXJQMNHJWSHET-UHFFFAOYSA-N N-[4-(3-chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide Chemical compound C=12C=C(NC(=O)C=CCN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- IJADXWBHNRTJAH-UHFFFAOYSA-N 4-N-(3-chloro-4-fluorophenyl)-7-methylsulfanylquinazoline-4,6-diamine Chemical compound C=12C=C(N)C(SC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 IJADXWBHNRTJAH-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- QSDKHHKJCWNTCW-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(2,2,2-trifluoroethoxy)quinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=NC=NC1=CC(OCC(F)(F)F)=C2NC(=O)C=CCN1CCCCC1 QSDKHHKJCWNTCW-UHFFFAOYSA-N 0.000 claims 1
- ICDUDMAKDBBZOT-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(2,2-difluoroethoxy)quinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide Chemical compound C=12C=C(NC(=O)C=CCN3CCCCC3)C(OCC(F)F)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 ICDUDMAKDBBZOT-UHFFFAOYSA-N 0.000 claims 1
- GFMMDHSSOIPFTF-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(2-fluoroethoxy)quinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide Chemical compound C=12C=C(NC(=O)C=CCN3CCCCC3)C(OCCF)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 GFMMDHSSOIPFTF-UHFFFAOYSA-N 0.000 claims 1
- YIRMJUMHPHHBCF-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(2-fluoroethylsulfanyl)quinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide Chemical compound C=12C=C(NC(=O)C=CCN3CCCCC3)C(SCCF)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 YIRMJUMHPHHBCF-UHFFFAOYSA-N 0.000 claims 1
- JGGXWPNXZZHJAI-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(fluoromethoxy)quinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide Chemical compound C=12C=C(NC(=O)C=CCN3CCCCC3)C(OCF)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 JGGXWPNXZZHJAI-UHFFFAOYSA-N 0.000 claims 1
- QMDUDTAUUIGRAT-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(methylamino)quinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide Chemical compound C=12C=C(NC(=O)C=CCN3CCCCC3)C(NC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 QMDUDTAUUIGRAT-UHFFFAOYSA-N 0.000 claims 1
- CRKXEIAEAGVNNS-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(trifluoromethoxy)quinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=NC=NC1=CC(OC(F)(F)F)=C2NC(=O)C=CCN1CCCCC1 CRKXEIAEAGVNNS-UHFFFAOYSA-N 0.000 claims 1
- XDXLWHQJFSMJFZ-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-ethoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide Chemical compound C=12C=C(NC(=O)C=CCN3CCCCC3)C(OCC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XDXLWHQJFSMJFZ-UHFFFAOYSA-N 0.000 claims 1
- XYUWLBQNUJRXRJ-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-(2-fluoropiperidin-1-yl)but-2-enamide Chemical compound C=12C=C(NC(=O)C=CCN3C(CCCC3)F)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XYUWLBQNUJRXRJ-UHFFFAOYSA-N 0.000 claims 1
- XFXOYVZSTQCSQN-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-(3-fluoropiperidin-1-yl)but-2-enamide Chemical compound C=12C=C(NC(=O)C=CCN3CC(F)CCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XFXOYVZSTQCSQN-UHFFFAOYSA-N 0.000 claims 1
- YMQSEEOAYCTNQU-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-(4-fluoropiperidin-1-yl)but-2-enamide Chemical compound C=12C=C(NC(=O)C=CCN3CCC(F)CC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 YMQSEEOAYCTNQU-UHFFFAOYSA-N 0.000 claims 1
- CVPYBKFJICOOOM-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-propan-2-yloxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide Chemical compound C=12C=C(NC(=O)C=CCN3CCCCC3)C(OC(C)C)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 CVPYBKFJICOOOM-UHFFFAOYSA-N 0.000 claims 1
- RYNJCJGKEYFFCT-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-propoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide Chemical compound C=12C=C(NC(=O)C=CCN3CCCCC3)C(OCCC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 RYNJCJGKEYFFCT-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 208000014081 polyp of colon Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56887204P | 2004-05-06 | 2004-05-06 | |
| EP05732761A EP1746999B1 (en) | 2004-05-06 | 2005-04-25 | 4-phenylamino-quinazolin-6-yl-amides |
| PCT/IB2005/001139 WO2005107758A1 (en) | 2004-05-06 | 2005-04-25 | 4-phenylamino-quinazolin-6-yl-amides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01267B true ME01267B (me) | 2013-06-20 |
Family
ID=34965519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2012-2A ME01267B (me) | 2004-05-06 | 2005-04-25 | 4-fenilaminokinazolin-6-ilamidi |
Country Status (47)
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100885835B1 (ko) * | 2004-05-06 | 2009-02-26 | 워너-램버트 캄파니 엘엘씨 | 4-페닐아미노-퀴나졸린-6-일-아미드 |
| KR100735639B1 (ko) | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
| KR100929146B1 (ko) | 2006-06-28 | 2009-12-01 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 |
| RU2011141121A (ru) | 2009-03-11 | 2013-04-20 | Окленд Юнисервисиз Лимитед | Пролекарственные формы ингибиторов киназ и их применение в терапии |
| CN102146059A (zh) * | 2010-02-08 | 2011-08-10 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、制备方法及其应用 |
| CN102382065B (zh) * | 2010-08-30 | 2014-05-28 | 山东轩竹医药科技有限公司 | 苯胺取代的喹唑啉衍生物 |
| CN102382106A (zh) | 2010-08-30 | 2012-03-21 | 黄振华 | 苯胺取代的喹唑啉衍生物 |
| CN102452989B (zh) * | 2010-10-19 | 2014-10-22 | 山东轩竹医药科技有限公司 | 苯胺取代的喹唑啉衍生物 |
| US8828391B2 (en) | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| JP5859118B2 (ja) * | 2011-05-26 | 2016-02-10 | 山東軒竹医薬科技有限公司 | チロシンキナーゼ阻害剤としてのキナゾリン誘導体、その調製方法及びその使用 |
| CN102838590B (zh) * | 2011-06-21 | 2014-07-09 | 苏州迈泰生物技术有限公司 | 氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途 |
| WO2013053206A1 (en) * | 2011-10-12 | 2013-04-18 | Teligene Ltd | Quinazoline derivatives as kinases inhibitors and methods of use thereof |
| CN104080774B (zh) | 2012-01-17 | 2017-02-22 | 安斯泰来制药株式会社 | 吡嗪甲酰胺化合物 |
| CN104350049B (zh) | 2012-05-07 | 2016-07-13 | 苏州韬略生物科技有限公司 | 作为激酶抑制剂的取代氨基喹唑啉 |
| TWI609012B (zh) | 2013-04-28 | 2017-12-21 | 廣東東陽光藥業有限公司 | 氨基喹唑啉類衍生物及其鹽和使用方法 |
| CN103288759B (zh) * | 2013-05-16 | 2015-05-20 | 苏州明锐医药科技有限公司 | 达克米替尼的制备方法 |
| CN103288758B (zh) * | 2013-05-16 | 2015-01-21 | 苏州明锐医药科技有限公司 | 一种达克米替尼的制备方法 |
| CN105408334B (zh) | 2013-05-21 | 2017-10-10 | 江苏迈度药物研发有限公司 | 作为激酶抑制剂的取代的吡唑并嘧啶类化合物 |
| CN103304492B (zh) * | 2013-06-20 | 2015-12-23 | 湖南欧亚生物有限公司 | 一种EGFR抑制剂Dacomitinib的合成方法 |
| ES2784664T3 (es) * | 2013-07-18 | 2020-09-29 | Shanghai Fochon Pharmaceutical Co Ltd | Derivados de quinazolina, composiciones de los mismos y uso como productos farmacéuticos. |
| CN105859641B (zh) * | 2015-05-05 | 2018-11-16 | 杭州华东医药集团新药研究院有限公司 | 喹唑啉巴豆基化合物二马来酸盐的晶体及其制备方法和用途 |
| AU2017204973A1 (en) * | 2016-01-06 | 2018-07-12 | Trillium Therapeutics Inc. | Novel fluorinated quinazoline derivatives as EGFR inhibitors |
| CN107721985A (zh) * | 2016-08-12 | 2018-02-23 | 山东轩竹医药科技有限公司 | 喹唑啉类酪氨酸激酶抑制剂的晶型 |
| CN107721986A (zh) * | 2016-08-12 | 2018-02-23 | 山东轩竹医药科技有限公司 | 喹唑啉类酪氨酸激酶抑制剂的晶型 |
| CN107721987A (zh) * | 2016-08-12 | 2018-02-23 | 山东轩竹医药科技有限公司 | 喹唑啉类酪氨酸激酶抑制剂的晶型 |
| CN107793368B (zh) * | 2016-08-31 | 2021-10-15 | 四川科伦药物研究院有限公司 | 达可替尼溶剂化物、其新晶型及其制备方法和用途 |
| KR102213040B1 (ko) * | 2017-12-20 | 2021-02-05 | 한국원자력의학원 | 방사선 손상 보호 또는 완화, 및 폐섬유화 예방 또는 치료 용도 |
| CN109438423A (zh) * | 2018-09-12 | 2019-03-08 | 通化师范学院 | 一种肺癌靶向化合物azd-3759的合成工艺的新方法 |
| KR20210137422A (ko) | 2018-09-25 | 2021-11-17 | 블랙 다이아몬드 테라퓨틱스, 인코포레이티드 | 티로신 키나아제 억제제로서의 퀴나졸린 유도체, 조성물, 이들의 제조 방법 및 이들의 용도 |
| CN113195000A (zh) | 2018-12-21 | 2021-07-30 | 第一三共株式会社 | 抗体-药物缀合物和激酶抑制剂的组合 |
| JP2022526159A (ja) | 2019-03-29 | 2022-05-23 | アストラゼネカ・アクチエボラーグ | 非小細胞肺がんの治療に使用するためのオシメルチニブ |
| AU2020328598A1 (en) * | 2019-08-15 | 2022-03-03 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
| US20210161897A1 (en) | 2019-11-12 | 2021-06-03 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| CN113045541A (zh) * | 2019-12-27 | 2021-06-29 | 广东东阳光药业有限公司 | Egfr抑制剂新晶型及其制备方法 |
| AU2021211871A1 (en) | 2020-01-20 | 2022-09-08 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| CN113717111A (zh) * | 2020-05-25 | 2021-11-30 | 苏州晶云药物科技股份有限公司 | 喹唑啉类化合物的晶型及其制备方法 |
| US20210369709A1 (en) | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
| JP2023533982A (ja) | 2020-07-10 | 2023-08-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Ｇａｓ４１阻害剤及びその使用方法 |
| CN112707869B (zh) * | 2020-12-25 | 2022-03-22 | 扬子江药业集团有限公司 | 一种达可替尼杂质及其制备方法 |
| CN119278041A (zh) | 2022-03-31 | 2025-01-07 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的与akt抑制剂组合的表皮生长因子受体（egfr）酪氨酸激酶抑制剂 |
| US20240116926A1 (en) | 2022-04-28 | 2024-04-11 | Astrazeneca Ab | Heteroaromatic compounds |
| IL316475A (en) | 2022-04-28 | 2024-12-01 | Astrazeneca Ab | Heterocyclic Condensed Compounds and Their Use in Cancer Therapy |
| WO2023209090A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their application in the treatment of cancer |
| WO2023209088A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| CN119421895A (zh) | 2022-06-27 | 2025-02-11 | 阿斯利康(瑞典)有限公司 | 涉及用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂的组合 |
Family Cites Families (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1340821C (en) | 1988-10-06 | 1999-11-16 | Nobuyuki Fukazawa | Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components |
| WO1991004027A1 (en) | 1989-09-15 | 1991-04-04 | Pfizer Inc. | New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat) |
| US5362878A (en) | 1991-03-21 | 1994-11-08 | Pfizer Inc. | Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) |
| CZ281628B6 (cs) | 1991-07-29 | 1996-11-13 | Warner-Lambert Company | Deriváty chinazolinu a farmaceutické přípravky na jejich bázi |
| US5366987A (en) | 1991-08-22 | 1994-11-22 | Warner-Lambert Company | Isoxazolyl-substituted alkyl amide ACAT inhibitors |
| DE69214827T2 (de) | 1991-08-22 | 1997-03-06 | Warner-Lambert Co., Ann Arbor, Mich. | Tetrazolamide als acat inhibitoren |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| US5412714A (en) * | 1992-02-24 | 1995-05-02 | At&T Corp. | Mnemonic and synonymic addressing in a telecommunications system |
| GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| PH31122A (en) | 1993-03-31 | 1998-02-23 | Eisai Co Ltd | Nitrogen-containing fused-heterocycle compounds. |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| MX9603593A (es) | 1994-02-23 | 1997-03-29 | Pfizer | Derivados de quinazolina. |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| TW321649B (OSRAM) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB9424233D0 (en) | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| DE69613367T2 (de) | 1995-04-27 | 2002-04-18 | Astrazeneca Ab, Soedertaelje | Chinazolin derivate |
| GB9508537D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| US6008230A (en) | 1995-10-16 | 1999-12-28 | Fujisawa Pharmaceutical Co., Ltd. | Quinoline compounds as H+ -ATPases |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| PT880508E (pt) | 1996-02-13 | 2003-07-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de vegf |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| GB9603097D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
| CN1116286C (zh) | 1996-03-05 | 2003-07-30 | 曾尼卡有限公司 | 4－苯胺基喹唑啉衍生物 |
| CN1145614C (zh) * | 1996-04-12 | 2004-04-14 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂，其制药用途及药物组合物 |
| GB9607729D0 (en) | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
| EP0912559B1 (en) | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US6225318B1 (en) | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
| ATE554750T1 (de) | 1997-03-05 | 2012-05-15 | Sugen Inc | Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| US5929080A (en) | 1997-05-06 | 1999-07-27 | American Cyanamid Company | Method of treating polycystic kidney disease |
| ES2201484T3 (es) | 1997-05-06 | 2004-03-16 | Wyeth Holdings Corporation | Utilizacion de compuestos de quinazolina para el tratamiento de la enfermedad de la poliquistosis renal. |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| US6251912B1 (en) | 1997-08-01 | 2001-06-26 | American Cyanamid Company | Substituted quinazoline derivatives |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| BR9814116A (pt) | 1997-11-06 | 2000-10-03 | American Cyanamid Co | Uso de derivados de quinazolina como inibidores de cinase de tirosina para tratamento de pólipo colÈnico |
| US6323209B1 (en) | 1997-11-06 | 2001-11-27 | American Cyanamid Company | Method of treating or inhibiting colonic polyps |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| HUP0102793A3 (en) | 1998-05-28 | 2002-07-29 | Parker Hughes Inst St Paul | Quinazolines for treating brain tumor and medicaments containing them |
| US6384223B1 (en) | 1998-07-30 | 2002-05-07 | American Home Products Corporation | Substituted quinazoline derivatives |
| BR9912575A (pt) | 1998-07-30 | 2001-05-02 | American Home Prod | Processo para a preparação de um composto, e, composto. |
| CZ303681B6 (cs) | 1998-09-29 | 2013-03-06 | Wyeth Holdings Corporation | Substituované deriváty 3-kyanochinolinu jako inhibitory proteintyrosinkináz |
| US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| EA003786B1 (ru) | 1998-11-19 | 2003-10-30 | Варнер Ламберт Компани | N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ |
| CZ20013079A3 (cs) | 1999-02-27 | 2001-11-14 | Boehringer Ingelheim Pharma Kg | Deriváty 4-aminochinazolinu a chinolinu |
| DE19911509A1 (de) | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| YU13200A (sh) | 1999-03-31 | 2002-10-18 | Pfizer Products Inc. | Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja |
| YU90901A (sh) | 1999-06-21 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh. & Co.Kg. | Biciklični heterocikli, lekovi koji sadrže ta jedinjenja, njihova primena i postupci za njihovo pripremanje |
| AUPQ113799A0 (en) * | 1999-06-22 | 1999-07-15 | University Of Queensland, The | A method and device for measuring lymphoedema |
| MXPA02001448A (es) | 1999-08-12 | 2002-07-02 | American Cyanamid Co | Farmacos antiinflamatorios no esteroides e inhibidores de cinasa del receptor del factor de crecimiento epidermico que contiene composicion para el tratamiento o la inhibicion de polipos colonicos y cancer colorrectal. |
| HK1046688A1 (zh) | 1999-09-21 | 2003-01-24 | Astrazeneca Ab | 喹唑啉化合物和含有喹唑啉化合物的藥物組合物 |
| US6664390B2 (en) | 2000-02-02 | 2003-12-16 | Warner-Lambert Company Llc | Method for the simplified production of (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazoline-4-yl]-amine or (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazoline-4-yl]-amine |
| US6384051B1 (en) | 2000-03-13 | 2002-05-07 | American Cyanamid Company | Method of treating or inhibiting colonic polyps |
| CN1240688C (zh) | 2000-04-07 | 2006-02-08 | 阿斯特拉曾尼卡有限公司 | 喹唑啉化合物 |
| US6627634B2 (en) | 2000-04-08 | 2003-09-30 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
| WO2001077104A1 (de) | 2000-04-08 | 2001-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| DE10031971A1 (de) | 2000-06-30 | 2002-01-10 | Goedecke Ag | Polymorphe Formen/Hydrate von N-[4-(3-Chlor-4-fluor-phenylamino)-7-(3-morpholin-4-yl-propoxy)-chinazolin-6-yl]-acrylamid Dihydrochlorid, Verfahren zu ihrer Herstellung sowie die Verwendung derselben zur Herstellung von Medikamenten mit irreversibler Tyrosinkinasehemmwirkung |
| US6446671B2 (en) * | 2000-08-04 | 2002-09-10 | John G. Armenia | Double wall safety hose |
| US6403580B1 (en) | 2000-08-26 | 2002-06-11 | Boehringer Ingelheim Pharma Kg | Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| US6740651B2 (en) | 2000-08-26 | 2004-05-25 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| US6617329B2 (en) | 2000-08-26 | 2003-09-09 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines and their use as medicaments |
| US6653305B2 (en) | 2000-08-26 | 2003-11-25 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
| US20020082270A1 (en) | 2000-08-26 | 2002-06-27 | Frank Himmelsbach | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| US6656946B2 (en) | 2000-08-26 | 2003-12-02 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| ES2282299T3 (es) | 2000-10-20 | 2007-10-16 | EISAI R&D MANAGEMENT CO., LTD. | Compuestos aromaticos con anillos de nitrogeno como agentes anticancerigenos. |
| US20030158196A1 (en) | 2002-02-16 | 2003-08-21 | Boehringer Ingelheim Pharma Gmbh Co. Kg | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors |
| DE10063435A1 (de) * | 2000-12-20 | 2002-07-04 | Boehringer Ingelheim Pharma | Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| PA8539401A1 (es) | 2001-02-14 | 2002-10-28 | Warner Lambert Co | Quinazolinas como inhibidores de mmp-13 |
| WO2002066445A1 (en) | 2001-02-21 | 2002-08-29 | Mitsubishi Pharma Corporation | Quinazoline derivatives |
| WO2002092577A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
| WO2002092578A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
| GB0118752D0 (en) | 2001-08-01 | 2001-09-26 | Pfizer Ltd | Process for the production of quinazolines |
| RU2004116911A (ru) | 2001-11-03 | 2005-11-10 | Астразенека Аб (Se) | Производные хиназолина в качестве противоопухолевых средств |
| GB0126433D0 (en) | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
| GB0128108D0 (en) | 2001-11-23 | 2002-01-16 | Astrazeneca Ab | Therapeutic use |
| CA2462149C (en) | 2001-11-30 | 2010-06-22 | Pfizer Products Inc. | Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth |
| BR0214499A (pt) | 2001-12-12 | 2005-05-10 | Pfizer Prod Inc | Derivados de quinazolina para o tratamento do crescimento anormal das células |
| DE60234125D1 (de) | 2001-12-24 | 2009-12-03 | Astrazeneca Ab | E inhibitoren |
| DE10204462A1 (de) | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
| DE60313956T2 (de) | 2002-02-26 | 2008-05-15 | Astrazeneca Ab | Pharmazeutische iressa zusammensetzung enthaltend ein wasserlösliches cellulosederivat |
| US7645878B2 (en) | 2002-03-22 | 2010-01-12 | Bayer Healthcare Llc | Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof |
| TWI324597B (en) | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
| DE10217689A1 (de) * | 2002-04-19 | 2003-11-13 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung |
| US20040044014A1 (en) | 2002-04-19 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
| US20030225079A1 (en) | 2002-05-11 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy |
| DE10221018A1 (de) * | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
| US20040048887A1 (en) | 2002-07-09 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors |
| PA8578001A1 (es) | 2002-08-07 | 2004-05-07 | Warner Lambert Co | Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas |
| EP1594504A4 (en) | 2003-01-23 | 2008-12-17 | T K Signal Ltd | NEW IRREVERSIBLE EGF RECEPTOR TYROSINE KINASE INHIBITORS AND THEIR USES FOR THERAPEUTIC AND DIAGNOSTIC PURPOSES |
| PE20040945A1 (es) * | 2003-02-05 | 2004-12-14 | Warner Lambert Co | Preparacion de quinazolinas substituidas |
| US7223749B2 (en) | 2003-02-20 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| EP1615910A1 (en) | 2003-04-09 | 2006-01-18 | Pfizer Products Inc. | Processes for the preparation of n-((((pyridinyloxy)-phenylamino)quinazolinyl)-allyl)acetamide derivatives and related compounds as well as intermediates of such processes and processes for the preparation of such intermediates |
| ATE390422T1 (de) | 2003-04-16 | 2008-04-15 | Astrazeneca Ab | Quinazolin-derivate für die behandling von krebs |
| BRPI0413745A (pt) | 2003-08-18 | 2006-10-24 | Pfizer Prod Inc | horário mde dosagem para agentes anticancerìgenos erbb2 |
| EP1673346A1 (en) | 2003-10-06 | 2006-06-28 | GPC Biotech AG | Quinazoline derivatives for the treatment of herpesviral infections |
| CA2547284A1 (en) | 2003-11-28 | 2005-06-09 | Mitsubishi Pharma Corporation | Quinazoline derivative and process for producing the same |
| KR100885835B1 (ko) * | 2004-05-06 | 2009-02-26 | 워너-램버트 캄파니 엘엘씨 | 4-페닐아미노-퀴나졸린-6-일-아미드 |
-
2005
- 2005-04-25 KR KR1020067023121A patent/KR100885835B1/ko not_active Expired - Lifetime
- 2005-04-25 EA EA200601849A patent/EA011237B1/ru active Protection Beyond IP Right Term
- 2005-04-25 HR HR20110958T patent/HRP20110958T1/hr unknown
- 2005-04-25 MX MXPA06012756A patent/MXPA06012756A/es active IP Right Grant
- 2005-04-25 DK DK05732761.1T patent/DK1746999T3/da active
- 2005-04-25 CA CA2565812A patent/CA2565812C/en not_active Expired - Lifetime
- 2005-04-25 KR KR1020087022983A patent/KR20080095915A/ko not_active Withdrawn
- 2005-04-25 PL PL05732761T patent/PL1746999T3/pl unknown
- 2005-04-25 EP EP05732761A patent/EP1746999B1/en not_active Expired - Lifetime
- 2005-04-25 WO PCT/IB2005/001139 patent/WO2005107758A1/en active Application Filing
- 2005-04-25 BR BRPI0510604A patent/BRPI0510604B8/pt active IP Right Grant
- 2005-04-25 AP AP2006003810A patent/AP2204A/xx active
- 2005-04-25 JP JP2007512544A patent/JP4205757B2/ja not_active Expired - Lifetime
- 2005-04-25 PT PT05732761T patent/PT1746999E/pt unknown
- 2005-04-25 AT AT05732761T patent/ATE533490T1/de active
- 2005-04-25 NZ NZ550796A patent/NZ550796A/en not_active IP Right Cessation
- 2005-04-25 RS RS20120004A patent/RS52119B/en unknown
- 2005-04-25 ES ES05732761T patent/ES2374553T3/es not_active Expired - Lifetime
- 2005-04-25 UA UAA200611675A patent/UA85706C2/ru unknown
- 2005-04-25 GE GEAP20059692A patent/GEP20084551B/en unknown
- 2005-04-25 ME MEP-2012-2A patent/ME01267B/me unknown
- 2005-04-25 CN CN2005800145175A patent/CN1972688B/zh not_active Expired - Lifetime
- 2005-04-25 AU AU2005239878A patent/AU2005239878B9/en not_active Expired
- 2005-04-25 SI SI200531429T patent/SI1746999T1/sl unknown
- 2005-04-29 MY MYPI20051908A patent/MY143566A/en unknown
- 2005-05-03 TW TW094114254A patent/TWI334865B/zh active
- 2005-05-03 PE PE2005000494A patent/PE20060215A1/es active IP Right Grant
- 2005-05-04 GT GT200500103A patent/GT200500103A/es unknown
- 2005-05-04 AR ARP050101797A patent/AR048652A1/es active IP Right Grant
- 2005-05-04 NL NL1028967A patent/NL1028967C2/nl not_active IP Right Cessation
- 2005-05-04 HN HN2005000192A patent/HN2005000192A/es unknown
- 2005-05-04 PA PA20058631901A patent/PA8631901A1/es unknown
- 2005-05-05 UY UY28885A patent/UY28885A1/es active IP Right Grant
- 2005-05-05 US US11/122,345 patent/US7772243B2/en active Active
-
2006
- 2006-10-23 IL IL178822A patent/IL178822A/en active IP Right Grant
- 2006-10-30 ZA ZA200609012A patent/ZA200609012B/xx unknown
- 2006-11-02 NI NI200600262A patent/NI200600262A/es unknown
- 2006-11-03 MA MA29435A patent/MA28632B1/fr unknown
- 2006-11-03 TN TNP2006000360A patent/TNSN06360A1/fr unknown
- 2006-11-03 CR CR8727A patent/CR8727A/es unknown
- 2006-11-08 EC EC2006006976A patent/ECSP066976A/es unknown
- 2006-12-06 NO NO20065626A patent/NO339692B1/no active Protection Beyond IP Right Term
-
2008
- 2008-07-11 JP JP2008180894A patent/JP4966923B2/ja not_active Expired - Lifetime
-
2010
- 2010-04-05 US US12/754,556 patent/US8466165B2/en active Active
-
2011
- 2011-12-02 CY CY20111101196T patent/CY1112127T1/el unknown
-
2013
- 2013-06-10 US US13/914,410 patent/US8623883B2/en not_active Expired - Lifetime
-
2019
- 2019-08-29 CY CY2019034C patent/CY2019034I1/el unknown
- 2019-09-10 LT LTPA2019016C patent/LTC1746999I2/lt unknown
- 2019-09-11 HU HUS1900039C patent/HUS1900039I1/hu unknown
- 2019-09-12 LU LU00127C patent/LUC00127I2/fr unknown
- 2019-09-12 FR FR19C1052C patent/FR19C1052I2/fr active Active
- 2019-09-12 BE BE2019C540C patent/BE2019C540I2/nl unknown
- 2019-09-13 NO NO2019035C patent/NO2019035I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME01267B (me) | 4-fenilaminokinazolin-6-ilamidi | |
| CA2698018C (en) | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | |
| ES2988336T3 (es) | Un agente antineoplásico 1-((4-(4-fluoro-2-metil-1H-indol-5-iloxi)-6-metoxiquinolin-7-iloxi)metil)ciclopropanamina, su forma cristalina y sus sales | |
| IL257219A (en) | Prodrugs of glutamine analogs | |
| WO2008094909A3 (en) | Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions | |
| CY1112800T1 (el) | Η χρηση υποκαθιστουμενων κυανοπυρρολιδινων για τη θεραπεια της υπερλιπιδαιμιας | |
| BRPI0610144A2 (pt) | método de preparar um 3-cianoquinolina substituìda; composto representado pela fórmula i; e composto, representado pela fórmula ii | |
| MX2010006182A (es) | Derivados de isoxazolo-piridazina. | |
| DK1539700T3 (da) | 8-hydroxyquinolin-derivater | |
| DE60002714D1 (de) | Substituierte azaoxindolederivate | |
| WO2007065662A3 (en) | Trisubstituted quinazolinone derivatives as vanilloid antagonists | |
| Kenawi et al. | Drug–drug interaction between diclofenac, cetirizine and ranitidine | |
| DE602005008953D1 (de) | Substituierte chinolinderivate als inhibitoren von mitotischem kinesin | |
| TW200716597A (en) | Novel piperidine-substituted indoles | |
| MX2009011836A (es) | Sales de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinaz olin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonilurea, en diferentes formas cristalinas, y composiciones farmaceuticas de las mismas. | |
| ATE466007T1 (de) | 5-substituierte indol-2-carbonsäureamidderivate | |
| CN110372666B (zh) | 喹唑啉类化合物作为egfr三突变抑制剂及其应用 | |
| MX2023012039A (es) | Compuestos bicíclicos fusionados sustituidos como inhibidores de parp y uso de estos. | |
| BG106806A (bg) | Нови съединения | |
| WO2007147770A3 (en) | Substituted phenyl methanone derivatives | |
| PL1613596T3 (pl) | Związki N-[(piperazynylo)heteroarylo]arylosulfonamidowe wykazujące powinowactwo do receptora dopaminy D3 | |
| ATE287397T1 (de) | Chinoline derivate und ihre anwendung als antitumor agentien | |
| WO2019029295A1 (zh) | 基于帕唑帕尼结构的hdac和vegfr双靶点抑制剂及其制备方法和应用 | |
| ATE509905T1 (de) | Benzamidderivate | |
| CA2351644A1 (en) | Pyrimidine derivatives and processes for the preparation thereof |